What Could Go Wrong With Recursion Pharmaceuticals Stock?
Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should track this figure closely, as the drug developer continues to lose money. Its drug programs remain in clinical trials, and it had a net loss of about $0.5 billion over the last twelve months. So how quickly is Recursion spending that cash?
Recursion Has Cut Its Cash Spending Plan
Recursion expects to spend $375 million in cash on its operations in 2026. The company lowered this forecast during its second-quarter call on August 5, 2026. The revised figure sits nearly 40% below comparable pro forma expenses for 2024.
Recursion attributed the reduced forecast to greater efficiency. By completing the same amount of work or more with fewer resources, the company kept advancing its drug programs while cutting costs. When asked whether further cuts might follow in the second half of the year, Recursion stood by the $375 million forecast.
Management believes the cash reserves will last through early 2028. Spending has slowed, yet Recursion’s operations continue to consume cash.
Recursion’s Sales Cover Little Of Its Spending
Recursion’s operations consumed about $0.4 billion of cash over the last twelve months, compared to the $557 million balance at the end of the second quarter. Current sales are too small to offset this outflow. Revenue over the same twelve months amounted to roughly a tenth of an operating loss of about $0.5 billion.
Revenue in the latest quarter also fell 61.8% compared to a year earlier. While a single quarter does not establish a trend, the drop leaves even less money coming in to cover the costs.
The stock price does not appear to reflect today’s sales. Recursion trades at 42.2 times sales, compared to 3.1 for the S&P 500. This valuation likely assumes the company’s drugs and partnerships will eventually earn far more than they do now. Even so, the stock has fallen 23% over the past twelve months, while the S&P 500 returned 17.1%. Over the past six months, however, Recursion shares gained 26%, while the S&P 500 returned 15.7%.
What Could Add To Recursion’s Cash?
Payments from partners could provide a source of additional cash. A collaboration with Roche-Genentech has generated more than $260 million in upfront and milestone payments so far. Management said each future small molecule program within that collaboration could earn more than $300 million in further milestones. These payments depend on a drug being developed and sold, meaning they are not money Recursion can count on today. Furthermore, the company noted that partnerships are structured to at least cover their direct costs from the start.
Shareholders have reason to be watchful, but not alarmed. Management does not expect the cash to run out before early 2028, and the company continues to reduce expenditures. The next scheduled catalyst arrives in November at the CGA-IGC Conference, where Recursion will present additional data on REC-4881, a drug candidate for a disease with no approved therapy. Full-year cash spending above the $375 million forecast would indicate the cash balance is running down faster than management planned.
How To Act On RXRX?
Now you know RXRX better. And that’s our purpose: to make you informed before you invest your money. However, making a bet on a single stock carries its own risks.
There is a smarter choice. Since its inception, the Trefis High Quality (HQ) Portfolio has beaten the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking.
If you’d rather act on RXRX itself:
| Play Offense | Play Defense |
|---|---|
| Learn More About RXRX & Invest | Save Taxes On Capital Gain |
| Earn From RXRX Cash Secured Puts | Covered Call Against RXRX |